

(51) International Patent Classification:
A61K 31/535 (2006.01)(21) International Application Number:
PCT/US2017/022564(22) International Filing Date:
15 March 2017 (15.03.2017)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

62/309,372	16 March 2016 (16.03.2016)	US
62/334,369	10 May 2016 (10.05.2016)	US
62/431,389	7 December 2016 (07.12.2016)	US
62/446,640	16 January 2017 (16.01.2017)	US

(71) Applicants: **KURA ONCOLOGY, INC.** [US/US]; 11119 North Torrey Pines Road, Suite 125, La Jolla, CA 92037 (US). **THE REGENTS OF THE UNIVERSITY OF MICHIGAN** [US/US]; 1600 Huron Parkway, 2nd Floor, Ann Arbor, MI 48109 (US).

(72) Inventors: **WU, Tao**; 2355 Terraza Guitara, Carlsbad, CA 92009 (US). **LI, Liansheng**; 13569 Arroyo Dale Lane, San Diego, CA 92130 (US). **WANG, Yi**; 7556 Charmant Drive, Apartment 1732, San Diego, CA 92122 (US). **REN, Pingda**; 5534 Havenridge Way, San Diego, CA 92130

(US). **GREMBECKA, Jolanta**; 1600 Huron Parkway, 2nd Floor, Ann Arbor, MI 48109 (US). **CIERPICKI, Tomasz**; 1600 Huron Parkway, 2nd Floor, Ann Arbor, MI 48109 (US). **KLOSSOWSKI, Szymon**; 1600 Huron Parkway, 2nd Floor, Ann Arbor, MI 48109 (US). **POLLOCK, Jonathan**; 1600 Huron Parkway, 2nd Floor, Ann Arbor, MI 48109 (US). **BORKIN, Dmitry**; 1600 Huron Parkway, 2nd Floor, Ann Arbor, MI 48109 (US).

(74) Agents: **CHANG, Andrew, L.** et al.; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, CA 94304-1050 (US).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

[Continued on next page]

(54) Title: SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHODS OF USE

FIG. 4



(57) Abstract: The present disclosure provides methods of inhibiting the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The methods are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin. Compositions for use in these methods are also provided.



GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*